Abstract
Background
Ecstasy is commonly used on weekends and linked to post-use mood declines. Laboratory studies with pure MDMA rarely detect residual effects, whereas naturalistic studies more often report mood reductions. The timing and contextual drivers of these effects remain unclear.
Methods
Data from seventeen participants reporting weekend ecstasy use (10 male, 7 female; 19–38 years) were drawn from a previously conducted study and analyzed for temporal mood changes not identified in the original report. Participants completed observation weeks following both ecstasy-use and nonuse weekends. Daily diaries assessed mood (0–10), other affective states, drug use, and sleep-related measures. Weekly BDI-II and BAI scores were collected.
Results
A significant Weekend Ecstasy X Day interaction was present (F(3,48) = 3.41, p = 0.037), driven by lower Monday mood after ecstasy-use weekends (t(16) = 2.36, p = 0.031). This effect remained after adjusting for other drug use (β = –1.44, p = 0.018), but was attenuated when hours in bed were included (β = –0.82, p = 0.17), which independently predicted lower mood (β = –0.29, p = 0.019). Mediation analyses indicated that increased time in bed largely accounted for the Monday decrease. No differences were found for the BDI-II and BAI. Exploratory analyses showed reduced Thursday physical tension/agitation after ecstasy-use weekends (p = 0.008).
Conclusions
Residual mood effects appear Monday-specific and are attenuated when inactivity is considered, suggesting recovery-related behavior—not MDMA alone—may underlie post-use mood declines. Because increased time in bed may both reflect and influence low mood, directionality cannot be determined.
Keywords: MDMA, Ecstasy, Mood, Daily diary, Naturalistic study
Graphical Abstract
Highlights
-
•
Monday mood dips after ecstasy-use weekends in daily diary reports.
-
•
Inactivity (more hours in bed) largely accounts for Monday mood decline.
-
•
Ecstasy weekends do not elevate Wednesday clinical depressive or anxiety symptoms.
-
•
Thursday shows reduced tension/agitation after weekend use, especially among females.
-
•
Behavioral factors may better explain mood effects than ecstasy alone.
1. Introduction
Ecstasy is widely used recreationally, most often on weekends (Hopper et al., 2006). Recent U.S. data indicate that approximately 2,013,000 individuals (0.7% of the population) reported past-year ecstasy use (Substance Abuse and Mental Health Services Administration., 2025). Although this represents a relatively small proportion of the general population, prevalence is substantially higher in specific subgroups; for example, past-year rates approaching 40% have been reported among adults attending electronic dance music night clubs and festivals (Palamar et al., 2023). Concerns about residual effects on mood have led to popularized concepts such as “midweek blues,” “blue Mondays,” or “suicide Tuesdays” (Parrott, 2013; Sessa, 2022). However, the specific weekday on which these residual mood disruptions occur remains uncertain.
Because street ecstasy varies widely in purity and may not contain 3,4-methylenedioxymethamphetamine (MDMA) (Hendy, 2021), we use “MDMA” to refer to the pure compound and “ecstasy” when the drug’s composition is uncertain.
Controlled laboratory studies using pure MDMA typically do not detect depressed mood in the days after administration (Bosker et al., 2010, Kirkpatrick et al., 2012, Borissova et al., 2021), and in some cases even report improved mood (Sessa, 2019; Sessa et al., 2022). In contrast, naturalistic studies of recreational ecstasy—which varies in purity and actual content, is often combined with alcohol or other drugs, and is often consumed in physically demanding nightlife settings—more consistently report post-use mood dips (Parrott and Lasky, 1998, Verheyden et al., 2002, Verheyden et al., 2003, Curran et al., 2004, Hoshi et al., 2006, Blankers et al., 2025). These contextual factors may underlie or exacerbate the mood changes attributed to ecstasy itself. Therefore, controlling for factors related to sleep and polydrug use is essential for isolating the unique contribution of ecstasy to post-use mood changes.
The present secondary analysis was conducted to answer the following questions: (1) Does weekend ecstasy use produce a residual mood effect on subsequent weekdays? If confirmed, two additional questions arise (2) Does this effect emerge on a specific day of the week? and (3) Does the effect hold after adjusting for relevant covariates (e.g., sleep measures and polydrug use)? In addition, given prior evidence that women may be more vulnerable to post-use mood reductions (Verheyden et al., 2002), an exploratory sex-based analysis was conducted.
2. Methods
2.1. Participants
In the original study by Hopper et al., (2006), 22 participants were recruited from the Boston metropolitan area via newspaper and internet advertisements. Eligibility was determined through a telephone interview and comprehensive in-person assessments at McLean Hospital. Inclusion criteria required a history of ecstasy use at least once per month during the preceding three months, no current psychotropic medication use, and no major psychiatric diagnoses other than DSM-IV substance abuse or dependence. Female participants were required to provide a negative pregnancy test, and all participants underwent a physical examination and electrocardiogram to ensure they were physically healthy.
Upon confirmation that inclusion but not exclusion criteria were met on enrollment, participants were provided a week’s worth of daily diary paper forms to complete in pen. Participants were instructed to complete the diary each morning upon awakening, record the date and time, and report on the previous day’s experiences and behavior. Participants returned to the laboratory for a study visit approximately every 7 days, primarily in the morning. At these weekly study visits, the daily diaries were collected, and clinical assessments were administered.
The original study procedures were approved by the Institutional Review Board at McLean Hospital. Participants read and signed an informed consent before any study procedures were performed and were paid for their participation in the study. All were enrolled between April 2002 and September 2004. The present study involved secondary analysis of de-identified data and was conducted in accordance with institutional guidelines.
2.2. Additional inclusion criteria for present analysis
For the present secondary analysis, additional inclusion criteria were applied. Participants had to have one weekend with ecstasy use followed by four consecutive weekdays (Monday-Thursday) without ecstasy use, as well as one weekend without ecstasy use followed by weekdays without ecstasy use (See Table 1). This requirement allowed for within-subject contrasts between weekdays following ecstasy-use weekends and weekdays following nonuse weekends. Two participants (one female, one male) reported their only ecstasy use on a Thursday rather than on Friday, Saturday, or Sunday. Because many recreational events, concerts, and club nights occur on Thursdays, we treated these cases as weekend ecstasy-use episodes. Participants reported their sex as male or female on study intake forms. Because no additional information (e.g., sex assigned at birth, gender identity) were collected, we refer to this variable as sex (female/male as reported). Of the 22 participants originally enrolled in Hopper et al., (2006), 17 (ten male, seven female), aged 19–38 years reported both ecstasy use and nonuse weekends and so were included in the present analysis.
Table 1.
Example week structure for ecstasy use (Week A) and nonuse (Week B) conditions.
| Week A (Ecstasy use weekend) | ||||||
|---|---|---|---|---|---|---|
| Friday | Saturday | Sunday | Monday | Tuesday | Wednesday | Thursday |
| At least one ecstasy use | No ecstasy use | |||||
| Daily diary (e.g., Mood) | Daily diary | Daily diary, clinical measures (i.e., BDI-II & BAI) | Daily diary | |||
| Week B (Non-ecstasy use weekend) | ||||||
| Friday | Saturday | Sunday | Monday | Tuesday | Wednesday | Thursday |
| No ecstasy use | ||||||
| Daily diary | Daily diary | Daily diary, clinical measures | Daily diary | |||
Table 1. Two samples of weeks representative of each participant’s data in the final analysis. Each participant contributed one ecstasy-use weekend (Week A) and one nonuse weekend (Week B), each followed by four weekdays of non-ecstasy use. In this example, the participant reported ecstasy use on Friday and Saturday during Week A and abstained during Week B. Daily diary ratings (e.g., mood) were collected throughout both weeks, and clinical measures (BDI-II, BAI) were administered on Wednesdays. This design enabled within-participant comparisons of weekday mood following ecstasy-use versus nonuse weekends.
2.3. Daily diary measures
Participants completed daily diaries that assessed past 24-hour drug use, mood states, and sleep. Specifically, participants reported their use of “ecstasy”, “alcohol”, “tobacco”, “caffeine”, “cocaine”, “marijuana”, “hallucinogens (classical hallucinogens such as psilocybin, mescaline, LSD, DMT)”, “opiates”, and “other drugs (open-ended)”. Mood ratings included self-reported “mood”, “anxiety”, “irritability”, “concentration”, and “physical tension/agitation.” Our primary a priori outcome was “mood”, rated from 0 (“extremely low”—down, sad, blue, moody) to 10 (“extremely high”). We selected this measure because it explicitly referenced “blue” in the item wording, making it particularly sensitive to detecting the Monday or midweek “blues.” Participants also rated their “sleep” on a 0–10 scale (0 = extremely low– sleeping very little, 10 = extremely high– excessive sleeping) and provided an open-ended response for “hours spent in bed”.
2.4. Weekly clinical assessments
Participants completed weekly on-site clinical assessments at McLean Hospital, including the Beck Depression Inventory-II (BDI-II: Beck et al., 1996) and Beck Anxiety Inventory (BAI: Beck et al., 1988).
2.5. Statistical analyses
Because “mood” was the primary a priori outcome, we first conducted a repeated-measures ANOVA with Weekend Ecstasy Use (Yes/No) and Day of Week (Monday–Thursday) as within-subject factors. Significant main effects or interactions were further examined using post hoc paired-sample t-tests. Paired-sample t-tests were also used to compare weekly BDI-II and BAI scores following ecstasy-use versus nonuse weekends. If a significant ecstasy-related difference emerged, we next evaluated whether the effect persisted after adjusting for potential covariates using linear mixed-effects models. Covariates included weekend drug use (i.e., “alcohol”, “tobacco”, “caffeine”, “cocaine”, “marijuana”, “hallucinogens”, “opiates”, and “other drugs (open-ended)”), “sleep”, and hours spent in bed. To further clarify the processes underlying any significant mood effects, follow-up analyses were conducted to explore potential mediating or explanatory factors.
Exploratory analyses were conducted for the remaining daily diary mood outcomes (i.e., “anxiety”, “irritability”, “ability to concentrate”, “physical tension/agitation”), using repeated-measures ANOVAs with Weekend Ecstasy Use (Yes/No) and Day of Week (Monday-Thursday) as factors. All exploratory models were followed by paired-sample t-tests, regardless of the presence of significant main effects or interactions. Finally, exploratory sex-based analyses on daily diary mood outcomes were performed by including Sex as a between-subjects factor, converting the original repeated-measures ANOVA model into a mixed-model ANOVA. Independent-sample t-tests were then conducted between males and females, regardless of main effects or interactions, given the exploratory nature of these analyses.
Data were organized in Microsoft Excel (Microsoft Corporation, Redmond, WA) and imported into R (version 4.3.2; R Core Team, 2023) using RStudio (version 2023.12.1; Posit Software, Boston, MA) for statistical analyses and visualization. Repeated-measures and mixed-model ANOVAs were conducted using the ez package, linear mixed-effects models were estimated with lme4, mediation analyses using lavaan, and figures were generated using ggplot2.
3. Results
3.1. Mood (primary outcome)
Mauchly’s test indicated that the assumption of sphericity was met; therefore, uncorrected degrees of freedom are reported. The analysis revealed a significant Day × Weekend Ecstasy Use interaction, F(3, 48) = 3.41, p = 0.037. As shown in Fig. 1, post hoc tests indicated that Monday mood was significantly lower following ecstasy-use weekends compared to nonuse weekends, t(16) = 2.36, p = 0.031. To confirm that the Monday effect represented a true post-use decline rather than only a difference between weekend ecstasy use and nonuse conditions, we conducted supplementary paired t-tests comparing Monday mood to mean weekend mood within each condition. This approach allowed us to test whether Monday mood after ecstasy-use weekends was significantly lower than both (1) weekend mood within the same condition and (2) Monday mood following nonuse weekends. Monday mood was significantly lower than weekend mood after ecstasy-use weekends (mean difference = –1.32, p = 0.036), whereas no such decline emerged after nonuse weekends (mean difference = 0.39, p = 0.573). Together, these findings indicate a Monday-specific mood decrease following weekend ecstasy use. Examination of individual trajectories showed that this effect was driven by most participants: 9 of 17 exhibited lower Monday mood following ecstasy-use weekends, 3 reported higher mood, and 5 showed no change (Fig. 2). No other weekday contrasts were significant (all p > 0.41)
Fig. 1.
Mood by Weekend Ecstasy Use and Day of Week. Mood was rated on a scale of zero (Extremely low: down, sad, blue, moody) to 10 (Extremely high). Mean mood ratings are shown for the weekend and subsequent weekdays following weekends with (filled circles) and without (open circles) ecstasy use. Error bars represent ±1 standard error of the mean (SEM). Mood was significantly lower on Monday following ecstasy use weekends compared to both weekend mood within the same condition and Monday mood following nonuse weekends. The two conditions converged by Tuesday and remained similar through Thursday. ⁎ indicates Monday mood significantly different from Monday after nonuse weekends (p < .05); + indicates Monday mood significantly different from weekend mood within the weekend ecstasy use condition (p < .05).
Fig. 2.
Mood on Monday by Weekend Ecstasy Use. Individual and group-level changes in Monday mood ratings as a function of weekend ecstasy use. Mood was rated on a scale of zero (Extremely low, down, sad, blue, moody) to 10 (Extremely high). Each dot represents one participant’s self-reported mood rating for Mondays following either a nonuse weekend (“No”) or an ecstasy-use weekend (“Yes”). The gray lines connect the same participant across the two conditions, illustrating within-subject changes in mood from nonuse to use weekends. The diamond symbol with error bars represents the mean mood rating and standard error for that condition. The asterisk indicates a statistically significant difference (p < 0.05). As shown, most participants reported lower Monday mood ratings after ecstasy-use weekends compared to nonuse weekends, indicated by the overall downward shift of points and the lower mean values in the “Yes” condition. Although some individual variability is evident, the pattern suggests a Monday-specific decrease in mood following ecstasy use.
3.2. Sensitivity analysis
Because two participants reported ecstasy use on a Thursday rather than during the Friday–Sunday period, we conducted a sensitivity analysis excluding them (n = 15). The direction of the Monday mood decrease remained consistent but only reached trend-level significance (p = 0.06) which is consistent with the reduced statistical power associated with the smaller subsample (n = 15). Given that Thursday use is common in naturalistic ecstasy-taking contexts (and by individuals with non-standard work schedules) and was defined a priori as part of the weekend window for this secondary analysis, the primary analyses retain these two participants.
3.3. Covariate and mediation analyses
The Monday mood decrease following ecstasy-use weekends remained significant after adjusting for other weekend drug use (β = –1.44, SE = 0.55, p = 0.018) and trended toward significance when controlling for subjective sleep time (β = –1.18, SE = 0.57, p = 0.053). Importantly, subjective sleep time was not disrupted—in fact, participants reported slightly higher sleep time on Mondays following ecstasy-use weekends (β = 0.76, SE = 0.52, p = 0.16), though this difference was not statistically significant. However, when hours spent in bed were included as a covariate, the ecstasy-use effect was attenuated and no longer significant (β = –0.82, SE = 0.57, p = 0.17), while greater time in bed predicted lower Monday mood (β = –0.29, SE = 0.12, p = 0.019). Together, these findings suggest that extended time in bed, rather than disrupted sleep, partially account for the post-weekend decline in mood.
A mediation model examined whether increased time spent in bed accounted for the Monday mood decrease following ecstasy-use weekends (Fig. 3). Weekend ecstasy use predicted a trend toward spending more time in bed on Monday (Path a: β = 1.63, p = 0.06), and greater time in bed predicted significantly lower Monday mood (Path b: β = –0.33, p = 0.005). The indirect effect (a × b: β = –0.53, p = 0.12) was nonsignificant but accounted for most of the total effect (Total: β = –1.29, p = 0.048), while the direct effect was no longer significant when bed hours were included (Path c’: β = –0.77, p = 0.22). This pattern indicates that increased time in bed largely explains the Monday mood decrease following ecstasy use and is consistent with a near-full mediation effect.
Fig. 3.
Mediation model examining the indirect effect of weekend ecstasy use on Monday mood through time spent in bed (“Bed Hours”). Weekend ecstasy use predicted a trend toward greater time spent in bed (path a: β = 1.63, p = 0.06), which in turn predicted significantly lower Monday mood (path b: β = –0.33, p = 0.005). The direct effect of ecstasy use on Monday mood (path c′: β = –0.77, p = 0.22) was no longer significant when bed hours were included, while the total effect remained significant (p = 0.048). The indirect effect (a × b: β = –0.53, p = 0.12) was nonsignificant but consistent with a pattern of near-full mediation, suggesting that increased time in bed largely explains the Monday mood decrease following ecstasy use.
3.4. Weekly clinical measures (BDI-II and BAI)
Ecstasy-use and nonuse weekends showed no significant difference in depressive symptoms (BDI-II: t(29.42) = 0.38, p = 0.71) and no significant difference in anxiety symptoms (BAI: t(31.05) = -0.98, p = 0.34).
3.5. Exploratory daily diary outcomes
No main effects or interactions were observed (all p > 0.11). However, exploratory post hoc comparisons indicated reduced physical tension/agitation following ecstasy-use weekends on Thursday (t(16) = 3.05, p = 0.008; Fig. 4).
Fig. 4.
Weekday Physical Tension and Agitation by Day of Week and Weekend Ecstasy Use. Mean daily physical tension and agitation ratings across the four weekdays following weekends with (filled circles) and without (open circles) ecstasy use. Error bars represent ±1 standard error of the mean (SEM). As shown, physical tension and agitation was significantly lower on Thursday following ecstasy-use weekends compared to nonuse weekends.
3.6. Exploratory sex-based analyses
No significant main effects or interactions involving sex were observed for any mood outcomes (all p > 0.30). However, exploratory comparisons suggested lower physical tension/agitation among females on Thursdays following ecstasy-use weekends (t(15) = 3.54, p = 0.003)
4. Discussion
This secondary analysis provides evidence that weekend ecstasy use predicts a Monday-specific decline in “mood”, with no effects evident on subsequent weekdays. This decrease was not reflected in weekly BDI-II scores, which showed no significant change following ecstasy-use weekends, underscoring the greater sensitivity of daily diary measures for detecting subtle post-use mood shifts. The Monday “dip” in mood persisted after accounting for other weekend drug use and subjective sleep time, indicating that neither factor explained the effect. Instead, when hours spent in bed were considered, the ecstasy-related mood decrease was attenuated, and greater time spent in bed independently predicted lower mood. A mediation model confirmed that ecstasy-use weekends tended to precede increased time spent in bed, which in turn predicted lower Monday mood, suggesting that inactivity rather than sleep loss was a strong explanatory pathway, nearly approaching full mediation.
Many naturalistic studies have reported post-use mood dips following recreational ecstasy use (e.g., Curran and Travill, 1997; Parrott and Lasky, 1998; Verheyden, 2002, 2003; Curran et al., 2004; Hoshi et al., 2006; Blankers et al., 2025). These effects are often attributed to nonpharmacological factors such as sleep deprivation (Scott et al., 2013) or polydrug use (Pirona and Morgan, 2010). In contrast, our findings suggest a different mechanism: participants spend more time in bed following ecstasy-use weekends, and this prolonged inactivity, rather than poor sleep quality, is associated with lower Monday mood. It is important to note that increased time in bed may be a consequence of low mood, as reduced initiation or engagement in daily activities is a hallmark symptom of depression (American Psychiatric Association., 2022). Future research incorporating objective, experimentally manipulated activity measures is warranted to clarify the direction of this relationship. Such findings could carry important practical implications. Educating people about possible post-use declines in activity and mood may help them better manage these temporary effects, which could otherwise disrupt daily obligations and increase work and school absenteeism.
Interestingly, exploratory analyses revealed that the Monday mood decline was followed by a positive effect later in the week: participants reported significantly lower levels of physical tension and agitation on Thursday following ecstasy-use weekends. This pattern resembles the “afterglow effect” described by Sessa and colleagues in clinical MDMA studies for alcohol use disorder, where participants reported improved mood in the days following MDMA administration (Sessa et al., 2022). Our finding is also consistent with McCann et al. (1994) who observed decreased impulsivity and hostility during a subacute period following ecstasy use. However, as this effect was exploratory, it should be interpreted cautiously.
Unlike most prior studies that assessed residual ecstasy effects at fixed time intervals (e.g., one to fourteen days post-use; Verheyden et al., 2002; Pirona and Morgan, 2010; Scott et al., 2013; Blankers et al., 2025), the present design captured mood on specific weekdays following weekend ecstasy use. This approach revealed a consistent Monday mood decrease and a potential Thursday reduction in physical tension and agitation, suggesting that post-use effects may follow a structured weekly pattern. Viewed in this context, our findings differ from those of a recent study by Blankers and colleagues (2025). In their within-participant study, participants reported a significant decrease in “mental well-being” across the three days following ecstasy use. Importantly, their outcome measure differed from ours: mental well-being was assessed using a composite score that included happy, relaxed, tired, stressed, and bored, whereas our primary outcome was a single-item “mood” rating. Notably, when Blankers et al. (2025) conducted a sensitivity analysis using a “positive” mental well-being composite including only happy and relaxed, the effect of ecstasy use was no longer significant. Residual effects emerged only when tired and bored—mood states that may reflect behavioral inactivity—were included.
Importantly, some prior work has examined residual ecstasy effects using a weekday-based design. Parrott and Lasky (1998) reported that Saturday ecstasy use was associated with elevated depressive symptoms on the Beck Depression Inventory (Beck et al., 1961) administered on Wednesday. In contrast, our BDI-II (Beck et al., 1996) assessments, also administered on Wednesdays, showed no significant increase in depressive symptoms following ecstasy-use weekends. The absence of elevated depression scores may reflect differences in measurement as the BDI-II, unlike the earlier version used by Parrott and Lasky (1998), was revised to align more closely with DSM-IV diagnostic criteria and likely provides a more accurate measure of clinically relevant depressive symptoms (Steer et al., 1997, Hailu Gebrie, 2018).
Exploratory analyses indicated that the reduction in physical tension and agitation was more pronounced among females. This Thursday decrease contrasts with prior reports of greater midweek mood disturbances in women (Verheyden et al., 2002). Differences in sample size and study design likely contributed to this discrepancy (our within-subjects design, n = 17, versus their between-subjects design, n = 80). In contrast, our results align with findings from McCann et al. (1994), who observed decreased impulsivity and hostility during the subacute period following ecstasy use, particularly among women. Given evidence that women are more sensitive to acute MDMA effects (Liechti et al., 2001, Yubero-Lahoz et al., 2011, Pardo-Lozano et al., 2012), these findings underscore the importance of further research to delineate sex-specific mood trajectories following MDMA use.
Our results also diverge from findings in controlled human pharmacology studies that administer pure MDMA to research volunteers, which typically do not detect post-use mood dips (Bosker et al., 2010, Kirkpatrick et al., 2012, Sessa et al., 2019). This discrepancy likely reflects the contextual differences between recreational and supervised clinical administration. Recreational ecstasy tablets vary in purity, are often “counterfeit”, are frequently combined with other substances, and are often taken in nightlife environments (Parrott, 2013). Individuals often engage in a variety of other activities such as prolonged dancing, that can result in elevated body temperature, dehydration, poor nutrition, and sleep deprivation, all factors that may contribute to negative mood effects the next day (Parrott, 2013). Consequently, many of the adverse aftereffects linked to recreational ecstasy may not generalize to clinically administered MDMA.
Daily diary measures are particularly sensitive to subtle mood changes that may be missed by clinical instruments such as the BDI-II. In this study, a modest Monday mood reduction (–1.4 points on a 0–10 scale) was evident in daily ratings but not reflected in weekly BDI-II scores, highlighting a discrepancy between these assessment approaches. Although small mood dips may not fall below clinical thresholds, they may still be meaningful for individuals near diagnostic cutoffs, where small shifts can influence clinical classification (Jacobson and Truax, 1992). Importantly, participants’ average Monday mood ratings remained near “normal” levels (~4–5 on the scale). Therefore, we should be careful to not pathologize what may be normal emotion variability.
Several additional limitations warrant consideration. First, the sample size was modest (n = 17), limiting statistical power and generalizability. In addition, paper-and-pen daily diaries may be vulnerable to retrospective completion and/or fabrication (Dale and Hagen, 2007). In an attempt address these limitations, daily diaries were collected in person weekly, reducing opportunities for extended backfilling and allowing timely review of entries. While this approach does not eliminate these limitations, it likely reduced their impact. Future studies could incorporate electronic diary methods to address issues of retrospective reporting and fabrication in real time.
The temporal context of data collection also warrants attention. The data were collected in the early 2000s, a period when the ecstasy market was characterized by frequent adulteration with non-MDMA stimulants (e.g., caffeine, methamphetamine, pseudoephedrine) and dissociatives such as dextromethorphan (DXM) and ketamine (Sevigny et al., 2024). In contrast, more recent data indicate that many of these adulterants are detected less frequently, and ecstasy is more likely to contain MDMA as the primary active ingredient. (Byrska and Stanaszek, 2025, Mounteney et al., 2018, Sevigny et al., 2024). Consequently, the composition of ecstasy during the study period may differ meaningfully from the current market, limiting temporal generalizability.
Relatedly, ecstasy use was assessed via self-report and was not chemically or biologically verified. Participants were not asked about the perceived contents or potential adulterants of the ecstasy they consumed. Although use was reported specifically as “ecstasy” in the daily diary, and it is reasonable to expect that if participants believed they had taken a different substance it would have been reported under another drug category, the actual composition cannot be confirmed. Notably, many participants described physical symptoms commonly associated with MDMA (e.g., jaw clenching, muscle pain, sweating). Finally, because the original study was not designed to examine residual mood effects, it did not include measures of hydration, physical exertion, cumulative ecstasy exposure, or same-day multiple dosing, all of which could plausibly contribute to the observed Monday mood dip.
Despite these caveats, the present findings make several important contributions. They demonstrate that ecstasy’s residual mood effects are specific to Monday rather than dispersed across the week, and critically, that these effects are substantially attenuated when behavioral inactivity (i.e., hours spent in bed) is considered. Although we cannot rule out that increased time in bed may be a result of low mood, the attenuation of the weekend ecstasy use effect on Monday mood, along with the near-full mediation, suggests that inactivity is a plausible explanatory pathway for the Monday mood dip. This pattern of effects suggests that post-use mood disruptions may reflect inactivity, or an interaction between weekend ecstasy use and inactivity, rather than direct pharmacological aftereffects. At the same time, “hours spent in bed” does not distinguish between prolonged wakefulness prior to sleep and extended time in bed after waking, limiting our ability to precisely characterize this behavior. Nonetheless, these results refine the concept of “midweek lows” into a Monday-specific phenomenon and highlight the need to integrate measures of inactivity into future ecstasy research.
CRediT authorship contribution statement
Scott E. Lukas: Writing – review & editing, Visualization, Validation, Supervision, Resources, Project administration, Funding acquisition, Conceptualization. Christopher Medina-Kirchner: Writing – review & editing, Writing – original draft, Visualization, Validation, Project administration, Formal analysis, Data curation, Conceptualization.
Funding
The original study was supported by NIDA grants DA03994 and K05DA00343 (SEL). This secondary analysis was supported by NIDA grant T32DA015036 (CMK).
Author disclosures
The funding sources had no role in the analysis or interpretation of the data, or in the writing of the manuscript.
Declaration of Competing Interest
The authors declare no conflicts of interest.
Acknowledgments
We are grateful to James W. Hopper, Zhaohui Su, Alison R. Looby, Elizabeth T. Ryan, David M. Penetar, and Christopher M. Palmer for carrying out the original study that provided the data for this secondary analysis.
References
- American Psychiatric Association. (2022). Diagnostic and statistical manual of mental disorders (5th ed., text rev.). 10.1176/appi.books.9780890425787 [DOI]
- Beck A.T., Ward C.H., Mendelson M., Mock J., Erbaugh J. An Inventory for Measuring Depression. Arch. Gen. Psychiatry. 1961;4:561–571. doi: 10.1001/archpsyc.1961.01710120031004. [DOI] [PubMed] [Google Scholar]
- Beck A.T., Epstein N., Brown G., Steer R.A. An inventory for measuring clinical anxiety: Psychometric properties. J. Consult. Clin. Psychol. 1988;56:893–897. doi: 10.1037/0022-006X.56.6.893. [DOI] [PubMed] [Google Scholar]
- Beck, A.T., Steer, R.A., Brown, G.K., 1996. BDI-II, Beck Depression Inventory: Manual. Psychological Corporation.
- Blankers M., van Beek R., Spronk D., den Hollander W., Andree R., Freeman T.P., Grabski M., Curran H.V., Waldron J., van Laar M.W. Three-day blues after ecstasy/MDMA use: Evidence from a longitudinal and daily analysis in the European nightlife scene. Drug Alcohol Depend. 2025;276 doi: 10.1016/j.drugalcdep.2025.112881. [DOI] [PubMed] [Google Scholar]
- Borissova A., Ferguson B., Wall M.B., Morgan C.J., Carhart-Harris R.L., Bolstridge M., Bloomfield M.A., Williams T.M., Feilding A., Murphy K., Tyacke R.J., Erritzoe D., Stewart L., Wolff K., Nutt D., Curran H.V., Lawn W. Acute effects of MDMA on trust, cooperative behaviour and empathy: A double-blind, placebo-controlled experiment. J. Psychopharmacol. 2021;35:547–555. doi: 10.1177/0269881120926673. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bosker W.M., Kuypers K.P.C., Conen S., Ramaekers J.G. Dose-related effects of MDMA on psychomotor function and mood before, during, and after a night of sleep loss. Psychopharmacol. 2010;209:69–76. doi: 10.1007/s00213-009-1767-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Byrska B., Stanaszek R. Chemical composition of Ecstasy tablets seized in Poland between 2005 and 2020. Forensic Toxicol. 2025;43:22–32. doi: 10.1007/s11419-024-00691-3. [DOI] [PubMed] [Google Scholar]
- Curran H.V., Travill R.A. Mood and cognitive effects of ± 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’): week-end ‘high’ followed by mid-week low. Addiction. 1997;92:821–831. doi: 10.1111/j.1360-0443.1997.tb02951.x. [DOI] [PubMed] [Google Scholar]
- Curran H.V., Rees H., Hoare T., Hoshi R., Bond A. Empathy and aggression: two faces of ecstasy? A study of interpretative cognitive bias and mood change in ecstasy users. Psychopharmacology. 2004;173:425–433. doi: 10.1007/s00213-003-1713-6. [DOI] [PubMed] [Google Scholar]
- Dale O., Hagen K.B. Despite technical problems personal digital assistants outperform pen and paper when collecting patient diary data. J. Clin. Epidemiol. 2007;60:8–17. doi: 10.1016/j.jclinepi.2006.04.005. [DOI] [PubMed] [Google Scholar]
- Hailu Gebrie M. An Analysis of Beck Depression Inventory 2nd Edition (BDI-II) Glob. J. Endocrinol. Metab. 2018;2 doi: 10.31031/GJEM.2018.02.000540. [DOI] [Google Scholar]
- Hendy K. MDMA Is Not Ecstasy: The Production of Pharmaceutical Safety through Documents in Clinical Trials. Med Anthr. Q. 2021;35:5–24. doi: 10.1111/maq.12548. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hopper J.W., Su Z., Looby A.R., Ryan E.T., Penetar D.M., Palmer C.M., Lukas S.E. Incidence and patterns of polydrug use and craving for ecstasy in regular ecstasy users: An ecological momentary assessment study. Drug Alcohol Depend. 2006;85:221–235. doi: 10.1016/j.drugalcdep.2006.04.012. [DOI] [PubMed] [Google Scholar]
- Hoshi R., Pratt H., Mehta S., Bond A.J., Curran H.V. An investigation into the sub-acute effects of ecstasy on aggressive interpretative bias and aggressive mood – are there gender differences? J. Psychopharmacol. 2006;20:291–301. doi: 10.1177/0269881106060505. [DOI] [PubMed] [Google Scholar]
- Jacobson N.S., Truax P. Methodological Issues & Strategies in Clinical Research. American Psychological Association; Washington, DC, US: 1992. Clinical significance: A statistical approach to defining meaningful change in psychotherapy research; pp. 631–648. [DOI] [PubMed] [Google Scholar]
- Kirkpatrick M.G., Gunderson E.W., Perez A.Y., Haney M., Foltin R.W., Hart C.L. A direct comparison of the behavioral and physiological effects of methamphetamine and 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology. 2012;219:109–122. doi: 10.1007/s00213-011-2383-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Liechti M.E., Gamma A., Vollenweider F.X. Gender differences in the subjective effects of MDMA. Psychopharmacol. (Berl. ) 2001;154:161–168. doi: 10.1007/s002130000648. [DOI] [PubMed] [Google Scholar]
- McCann U.D., Ridenour A., Shaham Y., Ricaurte G.A. Serotonin Neurotoxicity after (±)3,4-Methylenedioxymethamphetamine (MDMA; “Ecstasy”): A Controlled Study in Humans. Neuropsychopharmacol. 1994;10:129–138. doi: 10.1038/npp.1994.15. [DOI] [PubMed] [Google Scholar]
- Mounteney J., Griffiths P., Bo A., Cunningham A., Matias J., Pirona A. Nine reasons why ecstasy is not quite what it used to be. Int. J. Drug Policy. 2018;51:36–41. doi: 10.1016/j.drugpo.2017.09.016. [DOI] [PubMed] [Google Scholar]
- Palamar J.J., Salomone A., Massano M., Cleland C.M. Trends in reported and biologically confirmed drug use among people who use ecstasy in the nightclub/festival-attending population, 2016–2022. Drug Alcohol Depend. Rep. 2023;9 doi: 10.1016/j.dadr.2023.100198. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pardo-Lozano R., Farré M., Yubero-Lahoz S., O’Mathúna B., Torrens M., Mustata C., Pérez-Mañá C., Langohr K., Cuyàs E., Carbó M., Torre R. de la. Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”): The Influence of Gender and Genetics (CYP2D6, COMT, 5-HTT) PLOS ONE. 2012;7 doi: 10.1371/journal.pone.0047599. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Parrott A.C. Human psychobiology of MDMA or ‘Ecstasy’: an overview of 25 years of empirical research. Hum. Psychopharmacol. Clin. Exp. 2013;28:289–307. doi: 10.1002/hup.2318. [DOI] [PubMed] [Google Scholar]
- Parrott A.C., Lasky J. Ecstasy (MDMA) effects upon mood and cognition: before, during and after a Saturday night dance. Psychopharmacology. 1998;139:261–268. doi: 10.1007/s002130050714. [DOI] [PubMed] [Google Scholar]
- Pirona A., Morgan M.J. An investigation of the subacute effects of ecstasy on neuropsychological performance, sleep and mood in regular ecstasy users. J. Psychopharmacol. 2010;24:175–185. doi: 10.1177/0269881109102780. [DOI] [PubMed] [Google Scholar]
- Scott R.M., Hides L., Allen J.S., Lubman D.I. Subacute effects of ecstasy on mood: an exploration of associated risk factors. J. Psychopharmacol. 2013;27:53–61. doi: 10.1177/0269881112463467. [DOI] [PubMed] [Google Scholar]
- Sessa B., Sakal C., O’Brien S., Nutt D. First study of safety and tolerability of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy in patients with alcohol use disorder: preliminary data on the first four participants. BMJ Case Rep. 2019;12 doi: 10.1136/bcr-2019-230109. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sessa B., Aday J.S., O’Brien S., Curran H.V., Measham F., Higbed L., Nutt D.J. Debunking the myth of “Blue Mondays”: No evidence of affect drop after taking clinical MDMA. J. Psychopharmacol. 2022;36:360–367. doi: 10.1177/02698811211055809. [DOI] [PubMed] [Google Scholar]
- Sevigny E.L., Thyssen S., Erowid E., Lea R. Misrepresentation of MDMA in the United States, 1999–2023. Drug Alcohol Depend. 2024;264 doi: 10.1016/j.drugalcdep.2024.112467. [DOI] [PubMed] [Google Scholar]
- Steer R.A., Ball R., Ranieri W.F., Beck A.T. Further Evidence for the Construct Validity of the Beck Depression Inventory-II with Psychiatric Outpatients. Psychol. Rep. 1997;80:443–446. doi: 10.2466/pr0.1997.80.2.443. [DOI] [PubMed] [Google Scholar]
- Substance Abuse and Mental Health Services Administration . Center for Behavioral Health Statistics and Quality; 2025. 2024 National Survey on Drug Use and Health: Detailed tables. [Google Scholar]
- Verheyden S.L., Hadfield J., Calin T., Curran V.H. Sub-acute effects of MDMA (±3,4-methylenedioxymethamphetamine, “ecstasy”) on mood: evidence of gender differences. Psychopharmacology. 2002;161:23–31. doi: 10.1007/s00213-001-0995-9. [DOI] [PubMed] [Google Scholar]
- Verheyden S.L., Henry J.A., Curran H.V. Acute, sub-acute and long-term subjective consequences of ‘ecstasy’ (MDMA) consumption in 430 regular users. Hum. Psychopharmacol. Clin. Exp. 2003;18:507–517. doi: 10.1002/hup.529. [DOI] [PubMed] [Google Scholar]
- Yubero-Lahoz S., Pardo R., Farré M., O’Mahony B., Torrens M., Mustata C., Pérez-Mañá C., Carbó M.L., de la Torre R. Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans. Clin. Pharm. 2011;50:319–329. doi: 10.2165/11584550-000000000-00000. [DOI] [PubMed] [Google Scholar]





